上海合璞诉讼请求包括：由捷迈上海公司回购5.56亿元剩余库存商品，退还320.78万元预付款；由捷迈 上海公司支付0.92亿元利息损失以及承担库存产生的资金损失成本；由捷迈上海公司承担诉讼费、保全 费、律师费等。 此案的案号为（2025）沪01民初257号。步长制药公告称，本次诉讼事项法院已立案受理，尚未开庭审 理。 不过，天眼查数据显示，该案件开庭时间为12月16日，早于步长制药披露公告约两周。 步长制药方面称，前述5.5亿元左右存货存在计提存货跌价准备的风险，对公司本期利润及期后利润影 响金额尚不能确定。 （文章来源：中国经营报） 据了解，捷迈上海公司为国际知名骨科耗材企业捷迈邦美旗下公司。 公告显示，上海合璞与捷迈上海公司签订经销协议，成为捷迈上海公司的授权经销商。协议期满未续签 后，捷迈上海公司按行业惯例协调上海合璞所持有的其供应产品向新任授权经销商转移。 目前，上海合璞仍有5.5亿元左右存货尚未完成转移，且没有确切有效的库存转移计划，遂提起诉讼， 要求捷迈上海公司处理相关库存产品。 12月29日，步长制药（603858.SH）披露，控股子公司上海合璞医疗科技有限公司（以下简称"上海合 璞"）因合同纠 ...

12月29日康众医疗大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘折 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | | | | | 粤开证券股份有限公司深圳 | 西部证券股份有限 | | 26.55 | 1099.97 | 41.43 | -9.54 | 深南大道证券营业部 | 公司湖北分公司 | 康众医疗12月29日大宗交易平台出现一笔成交，成交量26.55万股，成交金额1099.97万元，大宗交易成 交价为41.43元，相对今日收盘价折价9.54%。该笔交易的买方营业部为粤开证券股份有限公司深圳深南 大道证券营业部，卖方营业部为西部证券股份有限公司湖北分公司。 （文章来源：证券时报网） 证券时报·数据宝统计显示，康众医疗今日收盘价为45.80元，上涨7.23%，日换手率为4.57%，成交额为 1.80亿元，全天主力资金净流入147.07万元，近5日该股累计上涨6.51%，近5日资金合计净流出630.93万 元。 两 ...

Group 1 - The core transaction of Beijing Baoren Medical Technology Co., Ltd. on December 29 involved a block trade of 18,100 shares, amounting to 2.0037 million yuan, with a transaction price of 110.70 yuan per share [2][3] - The buyer of the block trade was Huaxin Securities Co., Ltd. Shanghai Jingdong Road Securities Branch, while the seller was China Merchants Securities Co., Ltd. Shanghai Century Avenue Securities Branch [2][3] - On the same day, Baoren Medical's closing price was 110.70 yuan, reflecting a decrease of 0.29%, with a daily turnover rate of 0.20% and a total trading volume of 31.1217 million yuan [2][3] Group 2 - The latest margin financing balance for Baoren Medical is 282 million yuan, which has increased by 12.0934 million yuan over the past five days, representing a growth rate of 4.48% [3] - Baoren Medical was established on July 11, 2005, with a registered capital of 1.37748133 billion yuan [3]

消息面上，微创机器人-B近期公告，集团旗下腔镜、骨科、血管介入核心产品的综合订单量累计突破230台。其中，核心产品图迈腔镜手术机器人（简称"图 迈"）在全球范围内的商业化订单累计超过160台，含今年新获订单近120台。上述综合订单中，集团旗下各产品共完成商业化装机150余台。 此外，微创机器人-B还公告，集团自主研发的支气管镜手术机器人独道®UniPathTM电子支气管镜手术导航系统（简称"独道"）正式获得国家药品监督管理 局批准。这是集团引领全球手术机器人领域技术与应用发展的里程碑式突破，也标志着国产手术机器人在微无创诊疗关键技术路径上实现系统性全覆盖。 来源：上海证券报·中国证券网 上证报中国证券网讯（记者 孔令仪）12月29日早盘，微创机器人-B一度涨超24%，最高报26.48港元/股。截至10时38分，微创机器人-B涨23.40%，报26.16港 元/股。 | | | | | ZO.UOU | | --- | --- | --- | --- | --- | | | | | न्नेंटर | 26.040 | | | | | 买7 | 26.020 | | | | | 录8 | 26.000 | | ...

Core Viewpoint - Company Kubo Medical-B (02216) plans to acquire 157,800 shares of Series B preferred stock of Valgen Holding Corporation for $15 million, representing 1.05% of the target company's fully diluted shares as of the announcement date [1] Group 1: Acquisition Details - The acquisition is being made through Broncus China Holding Corporation, a wholly-owned subsidiary of Kubo Medical-B [1] - Valgen Holding Corporation specializes in providing systemic solutions for diseases such as mitral regurgitation and tricuspid regurgitation [1] - The products of Valgen include the DragonFly™ mitral valve repair device and the DragonFly-TTM tricuspid valve repair device [1] Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity to establish a comprehensive diagnostic and treatment platform for cardiopulmonary diseases, given the similarities and connections between structural heart diseases and pulmonary diseases [1] - The collaboration is expected to leverage the company's expertise in chronic obstructive pulmonary disease (COPD) to strengthen the foundation for a comprehensive cardiopulmonary diagnostic and treatment platform [1] - The acquisition also provides an opportunity to enhance the company's R&D capabilities by applying structural heart disease treatment technologies to pulmonary disease treatments and vice versa [1]

Core Viewpoint - Company Kubo Medical-B (02216) announced the acquisition of 157,800 shares of Series B preferred stock in Valgen Holding Corporation for a total consideration of $15 million, representing 1.05% of the target company's fully diluted and converted shares outstanding as of the announcement date [1] Group 1: Acquisition Details - The acquisition is being made by Broncus China Holding Corporation, a wholly-owned subsidiary of Kubo Medical-B [1] - Valgen Holding Corporation primarily provides systemic solutions for diseases such as mitral regurgitation and tricuspid regurgitation [1] - The products of Valgen include the DragonFly mitral valve repair device (via the transvenous approach) and the DragonFly-TTM tricuspid valve repair device [1] Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity for the company to achieve comprehensive diagnosis and treatment of cardiopulmonary diseases, given the similarities and correlations between structural heart diseases and pulmonary diseases [1] - The collaboration with Valgen will leverage the company's expertise in chronic obstructive pulmonary disease to establish a solid foundation for a comprehensive cardiopulmonary diagnosis and treatment platform [1] - The acquisition also provides an opportunity to enhance the company's R&D capabilities, applying structural heart disease treatment technologies to pulmonary disease treatments and vice versa [1]

鉴于结构性心脏病与肺部疾病之间存在相似性及关联性，董事会相信，收购事项提供了让集团得以实现 心肺疾病综合诊断及治疗的宝贵机会。凭藉公司在慢性阻塞性肺病方面的专业知识，与目标集团的合作 将使集团能够为建立心肺疾病综合诊断和治疗平台奠定坚实基础。 目标公司Valgen Holding Corporation为一家根据开曼群岛法律注册成立及存续的获豁免公司。目标集团 主要从事提供二尖瓣反流及三尖瓣反流等疾病的系统解决方案。其产品包括二尖瓣修复装置 DragonFly™(经股静脉途径)及三尖瓣修复装置DragonFly-T™。 格隆汇12月29日丨堃博医疗-B(02216.HK)公告，于2025年12月29日，买方Broncus China Holding Corporation(公司的全资附属公司)与卖方啓明医疗(香港)有限公司订立股份转让协议，据此，卖方有条 件同意出售，而买方有条件同意购买目标股份(占目标公司Valgen Holding Corporation截至本公告日期按 全面摊薄及转换基准计算的发行在外股份的1.05%，总代价为1500万美元(相等于约1.17亿港元)。 ...

Group 1 - The 44th J.P. Morgan Healthcare Conference (JPM) will be held from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants and featuring more than 500 listed companies and thousands of startups [2][10] - Chinese companies are increasingly competitive globally, with notable participation from WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiaries, as well as several Chinese pharmaceutical firms at the main venue [2][10] - The conference will focus on "capital + strategy," highlighting the importance of deep exchanges in the industry [2][10] Group 2 - China's pharmaceutical industry is characterized by "innovation upgrade + supply chain resilience," with overseas authorizations for innovative drugs exceeding the previous year's total in the first three quarters of 2025 [3][11] - The industry is undergoing a value reconstruction, emphasizing high-quality development, innovation, and compliance, with policies promoting diverse payment methods and medical service price reforms [3][11] - The domestic pharmaceutical chain is entering a commercialization phase, with a focus on supply chain security and the transition of domestic medical devices to mid-to-high-end markets [3][11] Group 3 - The investment outlook for 2026 is optimistic, with expectations for improved global liquidity favoring the pricing of innovative assets and government policies encouraging industry innovation [4][11] - The focus on internationalization is evident, with the Chinese pharmaceutical industry gradually gaining global competitiveness, particularly in innovative drugs and medical devices [4][12] - Marginal changes in policy and supply-demand relationships are expected to improve, particularly in the CXO sector, which has seen significant adjustments [4][12] Group 4 - The report suggests a focus on the integration of medical devices and traditional Chinese medicine, as well as certain pharmaceutical companies and state-owned enterprises [4][13] - The industry faces risks related to policy changes, including adjustments in research design requirements, pricing, and reimbursement policies, which could significantly impact development expectations [6][15] - There are also risks associated with unmet expectations in research and development, as well as potential delays in approval processes due to documentation and procedural changes [17]

证券日报网讯12月29日，爱迪特（301580）在互动平台回答投资者提问时表示，公司正在进行齿科数字 云系统的设计与开发，并密切关注相关技术在口腔医疗领域的研究与应用，积极探索技术创新和产业机 会。 ...

Core Viewpoint - Xinhua Medical (600587) acknowledges that its stock price fluctuations are influenced by multiple factors and emphasizes its efforts to maintain company value through various measures such as share buybacks by the controlling shareholder and optimizing dividends [1] Group 1 - The company has been actively engaging in share buybacks to support its stock price [1] - Xinhua Medical is optimizing its dividend policy as part of its strategy to enhance shareholder value [1] - The company recognizes that stock price volatility is affected by a range of factors beyond its control [1]